Edition:
India

Pieris Pharmaceuticals Inc (PIRS.OQ)

PIRS.OQ on NASDAQ Stock Exchange Capital Market

5.95USD
15 Dec 2017
Change (% chg)

$0.02 (+0.34%)
Prev Close
$5.93
Open
$5.93
Day's High
$6.07
Day's Low
$5.90
Volume
243,934
Avg. Vol
85,805
52-wk High
$6.65
52-wk Low
$1.35

Chart for

About

Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low... (more)

Overall

Beta: --
Market Cap(Mil.): $276.04
Shares Outstanding(Mil.): 44.31
Dividend: --
Yield (%): --

Financials

BRIEF-Pieris Pharma Received Clearance to Initiate Its First-In-Human Study In Australia For PRS-060/AZD1402

* PIERIS PHARMACEUTICALS - RECEIVED ETHICS AND REGULATORY CLEARANCE TO INITIATE ITS FIRST-IN-HUMAN STUDY IN AUSTRALIA FOR PRS-060/AZD1402

07 Dec 2017

BRIEF-Pieris Pharmaceuticals appoints James Geraghty as chairman of board of directors

* Pieris Pharmaceuticals appoints James Geraghty as chairman of the board of directors

21 Nov 2017

BRIEF-Pieris Pharmaceuticals reports Q3 loss per share $0.16

* Pieris Pharmaceuticals reports financial results for the third quarter ended september 30, 2017, and provides corporate update

09 Nov 2017

BRIEF-Pieris Pharmaceuticals names Allan Reine CFO

* Pieris Pharmaceuticals appoints Allan Reine, M.D., as chief financial officer Source text for Eikon: Further company coverage:

10 Aug 2017

BRIEF-Sichuan Kelun Pharmaceutical unit signs license agreement with Pieris Pharmaceuticals

* Says its Sichuan-based unit signs license agreement with Pieris Pharmaceuticals Inc, regarding a patent of tumour immunotherapy

10 Aug 2017

BRIEF-Pieris Pharmaceuticals Q2 loss per share $0.23

* Pieris Pharmaceuticals reports financial results for the second quarter ended June 30, 2017 and provides corporate update

10 Aug 2017

BRIEF-Pieris Pharma announces results from 2017 annual meeting of stockholders

* Pieris Pharmaceuticals announces results from 2017 annual meeting of stockholders and provides update on therapeutic programs

06 Jul 2017

Earnings vs. Estimates